Imugene's promising trial results: five patients with >30% decrease in tumour size
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Clinical stage immuno-oncology company, Imugene (ASX:IMU), has met all study endpoints and produced positive top-line results from its Phase 1b study of its HER-Vaxx gastric cancer vaccine.
14 patients, who all express the HER2 target protein, were tested three across three dose levels of HER-Vaxx (10, 30 and 50 micrograms) in combination with current standard of care chemotherapy, cisplatin and fluorouracil or capecitabine.
The response rate is considered an exploratory endpoint in the Phase 1b study, with results showing that of the 10 patients evaluable for tumour growth assessment during the study, five patients showed partial response (PR) and four patients showed stable disease (SD) for their best overall response.
Promisingly, all dose levels showed an increased antibody response in patients, no safety issues were reported, and HER-Vaxx was found to be well-tolerated.
As a result of the study, the Cohort Review Committee recommended a dose of 50 micrograms for the Phase 2 dose, based on the safety and immunogenicity data.
“We would like to sincerely thank the medical researchers and patients who participated in this study,” IMU managing director and CEO, Leslie Chong, said of the news.
“Together, we are cautiously encouraged by meeting all the endpoints of the study and data from the top-line results in a small sample size, in particular the five patients whose best response showed more than 30% decrease in their tumour size from baseline scans.”
“With these early results from the HER-Vaxx clinical study, Imugene’s B-cell active immunotherapy approach is showing positive signs, which provides us with further confidence in our B-cell immunotherapy pipeline.
“This is a promising milestone for Imugene and the many medical professionals seeking treatments for patients with advanced gastric cancer who often have very few medical options,” she said.
Phase 2 trial: first patient to be dosed in early 2019
The Phase 2 study will test the efficacy, safety and immune response to HER-Vaxx in 68 gastric cancer patients with metastatic gastric cancer over-expressing the HER-2 protein.
It will be randomised into two arms of either HER-Vaxx plus standard-of-care chemotherapy or standard-of-care alone. The primary endpoint will be overall survival and the secondary endpoint will be progression-free survival.
The study will be conducted at sites across Asia, Eastern Europe and India where treatments such as Herceptin and Perjeta are not readily available to patients. There is also a high prevalence of gastric cancer in many of the countries selected.
HER-Vaxx is designed to produce an antibody response against a cancer growth signal receptor protein called HER-2 which is found on the cell surface in breast and gastric cancers.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
